# US 2016/0251397 A1 · Akt-specific capture agents, compositions, and methods of using and making

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251397 A1
- Document ID: US20160251397A1
- Status: Published application
- Kind: A1
- Application number: 14/949,236
- Filed: 2015-11-23
- Published: 2016-09-01
- Earliest claimed: 2011-07-11
- Assignees: Indi Molecular, Inc.
- Applicants: Indi Molecular, Inc.
- Inventors: James R. Heath; Arundhati Nag; Samir Das; Kaycie M. Deyle; Steven Wesley Millward; Paul Edward Kearney
- Web page: https://patentgrep.com/patent/US20160251397A1

## CPC

- G01N 33/57545: of the ovaries
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/02: Linear peptides containing at least one abnormal peptide link
- C07K 14/001: {by chemical synthesis}
- C12N 15/1058: {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- C12Q 1/485: {involving kinase}
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/57575: {involving oncogenic proteins}
- G01N 33/57595: {involving intracellular compounds}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/91205: Phosphotransferases in general
- G01N 2333/91215: with a definite EC number (2.7.1.-)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.

## Claims

### Claim 1

A stable, synthetic triligand capture agent that specifically binds Akt, wherein the capture agent comprises an anchor ligand, a secondary ligand, and a tertiary ligand, and the capture agent binds to a non-ATP and non-peptide substrate binding site of Akt and wherein binding of said capture agent to the binding site allosterically inhibits Akt activity.

### Claim 2 (depends on 1)

The capture agent of claim 1, wherein said anchor ligand comprises the peptide sequence Az8-VFYRLGY-CONH2.

### Claim 3 (depends on 1)

The capture agent of claim 1, wherein said secondary ligand comprises the peptide sequence Pra-FWFLRG-CONH2.

### Claim 4 (depends on 1)

The capture agent of claim 1, wherein said tertiary ligand comprises the peptide sequence Ac-C8-RHERI-CONH2.

### Claim 5 (depends on 1)

The capture agent of claim 1, wherein said capture agent has the structure:

### Claim 6 (depends on 1)

The capture agent according to claim 1, wherein the linkage between one or more of the anchor ligand, secondary ligand, and tertiary ligand comprises a 1,4-substituted-1,2,3-triazole residue (Tz4).

### Claim 7 (depends on 1)

The use of a capture agent of claim 1 as a detection agent for detecting Akt in a biological sample.

### Claim 8 (depends on 1)

A method of detecting Akt in a biological sample using an immunoassay, wherein the immunoassay utilizes a capture agent of claim 1, and wherein said capture agent replaces an antibody or its equivalent in the immunoassay.

### Claim 9 (depends on 8)

The method of claim 8, wherein the immunoassay is selected from the group of Western blot, pull-down assay, dot blot, and ELISA.

### Claim 10 (depends on 1)

A method of treating a cancer associated with increased Akt expression and/or activity in a subject in need thereof, comprising administering a therapeutically effective amount of a capture agent of claim 1.

### Claim 11 (depends on 1)

A method of inhibiting Akt activity in a subject comprising administering to the subject a capture agent of claim 1.

### Claim 12 (depends on 11)

The method of claim 11, wherein administration of said capture agent inhibits Akt activity.

### Claim 13 (depends on 12)

The method of claim 12, wherein administration of said capture agent decreases the level of active Akt.

### Claim 14 (depends on 1)

A method of imaging a cancer associated with increased Akt expression and/or activity in a subject in need thereof, comprising administering an effective amount of a capture agent of claim 1.

### Claim 15 (depends on 1)

A method of treating a condition associated with increased Akt expression and/or activity in a subject in need thereof comprising administering to said subject an Akt capture agent of claim 1.

### Claim 16

A method of generating a capture agent for a target protein comprising:
(a) identifying an anchor ligand by the following steps:
(i) contacting the target protein with one or more target protein inhibitors;
(ii) preparing a first plurality of candidate peptides to select an anchor ligand for the target protein;
(iii) contacting the target protein with the first plurality of candidate peptides;
(iv) selecting a candidate peptide with affinity for the target protein as the anchor ligand, wherein the candidate peptide binds to the target protein outside of an active site; and
(v) sequencing the anchor ligand;
(b) identifying a secondary ligand by the following steps:
(i) preparing an anchor ligand selection block comprising the anchor ligand and an azido group or an alkynyl group;
(ii) preparing a second plurality of candidate peptides to select a secondary ligand for the target protein, the second plurality of peptides comprising an azido group or an alkynyl group if the anchor ligand selection block comprises an alkynyl group and azido group respectively;
(iii) contacting the anchor ligand selection block and the second plurality of peptides with the target protein;
(iv) providing a capture agent biligand by forming a disubstituted 1,2,3-triazole linkage between the anchor ligand selection block and the secondary ligand wherein the azido and alkynyl group of the anchor ligand selection block and the secondary ligand are brought in close proximity by binding to the target protein;
(v) selecting the capture agent biligand that has an affinity with the target protein; and
(vi) sequencing the secondary ligand;
(c) identifying a tertiary ligand and, optionally, additional ligands by the following steps:
(i) preparing a biligand selection block comprising an azido group or an alkynyl group; and
(ii) repeating steps (b)(ii) to (b)(vi) using a third plurality, fourth plurality, etc., of candidate peptides until a capture agent having desired binding affinity to the target protein is obtained.

### Claim 17 (depends on 16)

The method of claim 16, wherein said target protein is a kinase.

### Claim 18 (depends on 17)

The method of claim 17, wherein said kinase is Akt.

### Claim 19 (depends on 16)

The method of claim 16, wherein said active site is an ATP or substrate peptide binding site.

### Claim 20

A method of evaluating the efficiency and selectivity of an in situ click reaction between a first ligand and a second ligand comprising:
(a) carrying out an in situ click reaction between a soluble biotinylated first ligand and an on-bead second ligand;
(b) removing non-bound first ligand, such that all remaining first ligand is bound to said second ligand to form a ligand complex;
(c) contacting the ligand complex with a streptavidin-oligonucleotide QPCR template;
(d) subjecting the ligand complex-QPCR template to QPCR; and
(e) determining the cycle threshold for the QPCR reaction.

### Claim 21 (depends on 20)

The method of claim 20, wherein said first ligand is an anchor ligand and said second ligand is a secondary ligand.

### Claim 22 (depends on 20)

The method of claim 20, wherein said first ligand is a biligand and said second ligand is a tertiary ligand.

### Claim 23 (depends on 1)

The capture agent of claim 1, wherein the capture agent is stable in storage as a lyophilized powder.

### Claim 24 (depends on 1)

The capture agent of claim 1, wherein the capture agent is stable in storage at a temperature of about −80° C. to about 40° C.

### Claim 25 (depends on 1)

The capture agent of claim 1, wherein the capture agent is stable in storage at room temperature.

### Claim 26 (depends on 1)

The capture agent of claim 1, wherein the capture agent is stable in serum for at least 24 hours.

### Claim 27 (depends on 1)

The capture agent of claim 1, wherein the capture agent is stable at a pH in the range of about 3 to about 8.

### Claim 28 (depends on 1)

The capture agent of claim 1, wherein the capture agent is labeled with 64Cu DOTA, 68Ga DOTA, 18F, 64Cu, 68Ga, 89Zr, 124I, 86Y, 94mTc, 110mIn, 11C or 76Br.
